New Antimicrobial Molecules and New Antibiotic Strategies

 

 Buy Article Permissions and Reprints

ABSTRACT

Drug options for treatment of infections are increasingly limited. The pharmaceutical industry has found it difficult to discover new antimicrobial agents, and only two novel classes of antibiotics, the oxazolidinones and the cyclic lipopeptides, have entered the market since the late 1960s. Few new agents have reached the market in the last decade with potential interest for community-acquired pneumonia (CAP) treatment, including linezolid (the first oxazolidinone in clinical use), new fluoroquinolones, cefditoren, ertapenem, and telithromycin. Agents currently in clinical development include other novel quinolones and ketolides, broad-spectrum cephalosporin derivatives, faropenem, several glycopeptides, and iclaprim. Other molecules are considered to be promising candidates for the future. In addition to the foregoing agents, alternative treatment approaches have also been introduced into clinical practice, which include the administration of the appropriate antimicrobials in a timely manner and the consideration of the pharmacokinetic–pharmacodynamic properties of the agent(s).

REFERENCES

• 1 Coates A RM, Hu Y. Novel approaches to developing new antibiotics for bacterial infections.  Br J Pharmacol. 2007;  152 1147-1154
  CrossrefPubMedGoogle Scholar
• 2 Waldor M K. Disarming pathogens: a new approach for antibiotic development.  N Engl J Med. 2006;  354 296-297
  CrossrefPubMedGoogle Scholar
• 3 Mandell L A, Wunderink R G, Anzueto A et al.. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of Community-Acquired Pneumonia.  Clin Infect Dis. 2007;  44 S27-S72
  CrossrefPubMedGoogle Scholar
• 4 Felmingham D, Reinert R R, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin.  J Antimicrob Chemother. 2002;  50(Suppl S1) 25-37
  CrossrefPubMedGoogle Scholar
• 5 Bosso J A. The antimicrobial armamentarium: evaluating current and future treatment options.  Pharmacotherapy. 2005;  25(10 Pt 2) 55S-62S
  PubMedGoogle Scholar
• 6 Khardori N. Antibiotics – Past, present, and future.  Med Clin North Am. 2006;  90 1049-1076
  CrossrefPubMedGoogle Scholar
• 7 Fagon J, Patrick H, Haas D W et al.. Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin.  Am J Respir Crit Care Med. 2000;  161 753-762
  CrossrefPubMedGoogle Scholar
• 8 Hershberger E, Donabedian S, Konstantinou K, Zervos M J. Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology.  Clin Infect Dis. 2004;  38 92-98
  CrossrefPubMedGoogle Scholar
• 9 Paterson D L. Clinical experience with recently approved antibiotics.  Curr Opin Pharmacol. 2006;  6 486-490
  PubMedGoogle Scholar
• 10 Owens Jr R C, Ambrose P G. Antimicrobial safety: focus on fluoroquinolones.  Clin Infect Dis. 2005;  41(Suppl 2) S144-S157
  CrossrefPubMedGoogle Scholar
• 11 Van Bambeke F, Reinert R R, Appelbaum P C, Tulkens P M, Peetermans W E. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.  Drugs. 2007;  67 2355-2382
  CrossrefPubMedGoogle Scholar
• 12 Zhanel G G, Fontaine S, Adam H et al.. A review of new fluoroquinolones: focus on their use in respiratory tract infections.  Treat Respir Med. 2006;  5 437-465
  CrossrefPubMedGoogle Scholar
• 13 Kollef M H, Rello J, Cammarata S K, Croos-Dabrera R V, Wunderink R G. Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin.  Intensive Care Med. 2004;  30 388-394
  PubMedGoogle Scholar
• 14 Wilcox M H. Efficacy of linezolid versus comparator therapies in gram-positive infections.  J Antimicrob Chemother. 2003;  51(Suppl 2) ii27-ii35
  PubMedGoogle Scholar
• 15 San Pedro G S, Cammarata S K, Oliphant T H, Todisco T. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia.  Scand J Infect Dis. 2002;  34 720-728
  CrossrefPubMedGoogle Scholar
• 16 Potoski B A, Adams J, Clarke L et al.. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci.  Clin Infect Dis. 2006;  43 165-171
  CrossrefPubMedGoogle Scholar
• 17 Lodise T P, Kinzig-Schippers M, Drusano G L et al.. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.  Antimicrob Agents Chemother. 2008;  52 1945-1951
  CrossrefPubMedGoogle Scholar
• 18 Ortiz-Ruiz G, Vetter N, Isaacs R, Carides A, Woods G L, Friedland I. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.  J Antimicrob Chemother. 2004;  53(Suppl 2) ii59-ii66
  CrossrefPubMedGoogle Scholar
• 19 Alfageme I, Aspa J, Bello S et al.. Normativas para el diagnóstico y el tratamiento de la neumonía adquirida en la comunidad. Sociedad Española de Neumología y Cirugía de Tórax.  Arch Bronconeumol. 2005;  41 272-289
  CrossrefPubMedGoogle Scholar
• 20 American Thoracic Society . Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.  Am J Respir Crit Care Med. 2005;  171 388-416
  CrossrefPubMedGoogle Scholar
• 21 Schmidt-Ioanas M, de Roux A, Lode H. New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient.  Curr Opin Crit Care. 2005;  11 481-486
  CrossrefPubMedGoogle Scholar
• 22 Silverman J A, Mortin L I, Vanpraagh A D, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modelling and clinical impact.  J Infect Dis. 2005;  191 2149-2152
  CrossrefPubMedGoogle Scholar
• 23 Lonks J R, Goldmann D A. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections.  Clin Infect Dis. 2005;  40 1657-1664
  CrossrefPubMedGoogle Scholar
• 24 Wolter N, Smith A M, Low D E, Klugman K P. High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2007;  51 1092-1095
  PubMedGoogle Scholar
• 25 Clay K D, Hanson J S, Pope S D, Rissmiller R W, Purdum III P P, Banks P M. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review.  Ann Intern Med. 2006;  144 415-420
  CrossrefPubMedGoogle Scholar
• 26 Dore D D, Dibello J R, Lapane K L. Telithromycin use and spontaneous reports of hepatotoxicity.  Drug Saf. 2007;  30 697-703
  CrossrefPubMedGoogle Scholar
• 27 Van Bambeke F, Harms J M, Van Laethem Y, Tulkens P M. Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections.  Expert Opin Pharmacother. 2008;  9 267-283
  CrossrefPubMedGoogle Scholar
• 28 Doan T L, Fung H B, Mehta D, Riska P E. Tigecycline: a glycylcycline antimicrobial agent.  Clin Ther. 2006;  28 1079-1106
  CrossrefPubMedGoogle Scholar
• 29 Stein G E, Craig W A. Tigecycline: a critical analysis.  Clin Infect Dis. 2006;  43 518-524
  CrossrefPubMedGoogle Scholar
• 30 Zhanel G G, Wiebe R, Dilay L et al.. Comparative review of the carbapenems.  Drugs. 2007;  67 1027-1052
  CrossrefPubMedGoogle Scholar
• 31 Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.  Crit Care Med. 2008;  36 1089-1096
  CrossrefPubMedGoogle Scholar
• 32 Réa-Neto A, Niederman M, Lobo S M et al.. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.  Curr Med Res Opin. 2008;  24 2113-2126
  CrossrefPubMedGoogle Scholar
• 33 Keam S J, Perry C M. Prulifloxacin.  Drugs. 2004;  64 2221-2234
  CrossrefPubMedGoogle Scholar
• 34 Blasi F, Aliberti S, Tarsia P, Santus P, Centanni S, Allegra L. Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis.  Int J Chron Obstruct Pulmon Dis. 2007;  2 27-31
  PubMedGoogle Scholar
• 35 Jones R N, Sader H S, Stilwell M G, Fritsche T R. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae .  Diagn Microbiol Infect Dis. 2007;  58 1-7
  CrossrefPubMedGoogle Scholar
• 36 Hammerschlag M R, Reznik T, Roblin P M, Ramírez J, Summersgill J, Bukofzer S. Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae .  J Antimicrob Chemother. 2003;  51 1025-1028
  CrossrefPubMedGoogle Scholar
• 37 Hammerschlag M R, Sharma R. Use of cethromycin, a new ketolide, for the treatment of community-acquired respiratory infections.  Expert Opin Investig Drugs. 2008;  17 387-400
  CrossrefPubMedGoogle Scholar
• 38 Anderson S D, Gums J G. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.  Ann Pharmacother. 2008;  42 806-816
  CrossrefPubMedGoogle Scholar
• 39 Nicholson S C, Strauss R S, Michiels B, Noel G J. Efficacy of ceftobiprole for the treatment of severely ill patients with hospitalized community-acquired pneumonia [abstract].  Am J Respir Crit Care Med. 2008;  177 A677
  CrossrefPubMedGoogle Scholar
• 40 Biek D, Ge Y, Sahm D F. Activity of ceftaroline against common respiratory-associated pathogens from a collection of recent US isolates [abstract].  Am J Respir Crit Care Med. 2008;  177 A677
  CrossrefPubMedGoogle Scholar
• 41 Gettig J P, Crank C W, Philbrick A H. Faropenem medoxomil.  Ann Pharmacother. 2008;  42 80-90
  PubMedGoogle Scholar
• 42 Lentino J R, Narita M, Yu V L. New antimicrobial agents as therapy for resistant gram-positive cocci.  Eur J Clin Microbiol Infect Dis. 2008;  27 3-15
  PubMedGoogle Scholar
• 43 Attwood R J, LaPlante K L. Telavancin: a novel glycolipopeptide antimicrobial agent.  Am J Health Syst Pharm. 2007;  64 2335-2348
  CrossrefPubMedGoogle Scholar
• 44 Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens P M. Glycopeptide antibiotics: from conventional molecules to new derivatives.  Drugs. 2004;  64 913-936
  PubMedGoogle Scholar
• 45 Kohlhoff S A, Sharma R. Iclaprim.  Expert Opin Investig Drugs. 2007;  16 1441-1448
  CrossrefPubMedGoogle Scholar
• 46 Guay D R. Drug forecast: the peptide deformylase inhibitors as antibacterial agents.  Ther Clin Risk Manag. 2007;  3 513-525
  PubMedGoogle Scholar
• 47 Menéndez R, Torres A, Zalacain R et al.. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome.  Am J Respir Crit Care Med. 2005;  172 757-762
  CrossrefPubMedGoogle Scholar
• 48 Menéndez R, Torres A, Rodríguez de Castro F et al.. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients.  Clin Infect Dis. 2004;  39 1783-1790
  CrossrefPubMedGoogle Scholar
• 49 Meehan T P, Fine M J, Krumholz H M et al.. Quality of care process, and outcomes in elderly patients with pneumonia.  JAMA. 1997;  278 2080-2084
  CrossrefPubMedGoogle Scholar
• 50 Houck P M, Bratzler D W, Nsa W, Ma A, Bartlett J G. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.  Arch Intern Med. 2004;  164 637-644
  CrossrefPubMedGoogle Scholar
• 51 Berjohn C M, Fishman N O, Joffe M M, Edelstein P H, Metlay J P. Treatment and outcomes for patients with bacteremic pneumococcal pneumonia.  Medicine. 2008;  87 160-166
  CrossrefPubMedGoogle Scholar
• 52 Kanwar M, Brar N, Khatib R, Fakih M G. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule.  Chest. 2007;  131 1865-1869
  CrossrefPubMedGoogle Scholar
• 53 Waterer G W, Kessler L A, Wunderink R G. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia.  Chest. 2006;  130 11-15
  CrossrefPubMedGoogle Scholar
• 54 Schaaf B, Kruse J, Rupp J et al.. Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia.  Eur Respir J. 2007;  30 517-524
  CrossrefPubMedGoogle Scholar
• 55 Mufson M A, Stanek R J. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978–1997.  Am J Med. 1999;  107 34S-43S
  PubMedGoogle Scholar
• 56 Waterer G W, Somes G W, Wunderink R G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.  Arch Intern Med. 2001;  161 1837-1842
  CrossrefPubMedGoogle Scholar
• 57 Martinez J A, Horcajada J P, Almela M et al.. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.  Clin Infect Dis. 2003;  36 389-395
  CrossrefPubMedGoogle Scholar
• 58 Lodise T P, Kwa A, Cosler L, Gupta R, Smith R. Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.  Antimicrob Agents Chemother. 2007;  51 3977-3982
  CrossrefPubMedGoogle Scholar
• 59 Paul M, Nielsen A D, Gafter-Gvili A et al.. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis.  Eur Respir J. 2007;  30 525-531
  CrossrefPubMedGoogle Scholar
• 60 Mouton J W, Vinks A A. Continuous infusion of beta-lactams.  Curr Opin Crit Care. 2007;  13 598-606
  CrossrefPubMedGoogle Scholar
• 61 File T M. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.  Int J Antimicrob Agents. 2007;  30(Suppl 2) S131-S134
  CrossrefPubMedGoogle Scholar
• 62 Swainston Harrison T, Keam S J. Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.  Drugs. 2007;  67 773-792
  CrossrefPubMedGoogle Scholar
• 63 Li J Z, Winston L G, Moore D H, Bent S. Efficacy of short course antibiotic regimens for community-acquired pneumonia: a meta-analysis.  Am J Med. 2007;  120 783-790
  CrossrefPubMedGoogle Scholar
• 64 el Moussaoui R, de Borgie C AJM, van den Broek P et al.. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community-acquired pneumonia: randomised, double blind study.  BMJ. 2006;  332 1355-1360
  CrossrefPubMedGoogle Scholar
• 65 Anderson V R, Perry C M. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection.  Drugs. 2008;  68 535-565
  CrossrefPubMedGoogle Scholar
• 66 Christ-Crain M, Stolz D, Bingisser R et al.. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia.  Am J Respir Crit Care Med. 2006;  174 84-93
  CrossrefPubMedGoogle Scholar
• 67 Oosterheert J J, Bonten M JM, Schneider M ME et al.. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial.  BMJ. 2006;  333 1193-1197
  CrossrefPubMedGoogle Scholar
• 68 Nathan R V, Rhew D C, Murray C, Bratzler D W, Houck P M, Weingarten S R. In-hospital observation after antibiotic switch in pneumonia: a national evaluation.  Am J Med. 2006;  119 512.e1-512.e7
  PubMedGoogle Scholar
• 69 Carratalà J, García-Vidal C. What is healthcare-associated pneumonia and how is it managed?.  Curr Opin Infect Dis. 2008;  21 168-173
  CrossrefPubMedGoogle Scholar
• 70 Niederman M S. Recent advances in community-acquired pneumonia: inpatient and outpatient.  Chest. 2007;  131 1205-1215
  CrossrefPubMedGoogle Scholar
• 71 Rubinstein E, Kollef M H, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus .  Clin Infect Dis. 2008;  46(Suppl 5) S378-S385
  CrossrefPubMedGoogle Scholar
• 72 Micek S T, Dunne M, Kollef M H. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production.  Chest. 2005;  128 2732-2738
  CrossrefPubMedGoogle Scholar

Felipe Rodríguez de CastroPh.D. M.D. 

Servicio de Neumología, Hospital Universitario de Gran Canaria “Dr. Negrín,” Universidad de Las Palmas de Gran Canaria (ULPGC)

Barranco de la Ballena, s/n, 35010 Las Palmas, Spain

Email: frodcasw@gobiernodecanarias.org